Alle Storys
Folgen
Keine Story von Sartorius AG mehr verpassen.

Sartorius AG

euro adhoc: Sartorius AG
Financial Figures/Balance Sheet
Order intake (pro forma) rose 7.1%; currency-adjusted: +9.5% | Operating earnings above the previous year´s | Integration of Stedim progressing as planned | Growth and earnings targets for ...

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.
Figures for the first nine months 2007
31.10.2007
For the first time, the Sartorius Group is announcing the quarterly 
results for a reporting period after the combination of the Sartorius
Biotechnology Division with former Stedim S.A. The figures for order 
intake, sales revenue and earnings of the Biotechnology Division and 
the Group have therefore been growing on new levels. Thus, nine-month
order intake (pro forma) for the Sartorius Group in 2007 climbed 
26.4% relative to the figure published a year ago. For sales revenue,
the corresponding increase was 21.7%. Viewed from this angle, the 
Biotechnology Division´s order intake grew 47.2% and its sales 
revenue 38.4%. Based on this comparison, consolidated pro forma 
earnings before interest, taxes and amortization (EBITA) adjusted for
extraordinary expenses surged 32.5%.
To serve the purpose of ensuring the greatest possible transparency 
and comparability of the results of the reporting period with those 
of the year-earlier period, the following essentially presents and 
describes our corresponding pro forma figures:
Relative to the pro forma year-earlier figure, consolidated pro forma
order intake grew 7.1% to EUR479.7 million (PY: EUR447.9 million). 
Currency-adjusted, this corresponds to 9.5% growth. With a pro forma 
gain of 8.6% (currency-adjusted: 11.2%) to EUR283.8 million (PY: 
EUR261.3 mn), the Biotechnology Division posted considerable growth 
in order intake. The Mechatronics Division received orders worth 
EUR195.9 million (PY: EUR186.6 mn), which corresponds to a gain of 
5.0% (currency-adjusted: 7.2%). At EUR431.9 million (PY: EUR379.4 
mn), actual order intake of the Sartorius Group is 13.8% 
(currency-adjusted: 16.2%) above the year-earlier figure.
Pro forma consolidated sales revenue was EUR469.9 million (PY: 
EUR456.5 mn); this corresponds to growth of 2.9% or, 
currency-adjusted, 5.2%. The Biotechnology Division generated pro 
forma sales revenue of EUR281.8 million (PY: EUR274.1 mn) and thus 
achieved a gain of 2.8% or, currency-adjusted, 5.3%. The Mechatronics
Division grew 3.2% (currency-adjusted: 5.2%) to EUR188.2 million (PY:
EUR182.3 mn). Actual consolidated sales revenue climbed 9.8% 
(currency-adjusted: 12,0%) to EUR423.8 million (PY: EUR386.0 mn).
The Group achieved a pro forma underlying EBITA of EUR48.7 million 
(PY: EUR48.3 mn); the corresponding EBITA margin was 10.4% (PY: 
10.6%). Without the unfavorable impact of currency fluctuations, it 
would have reached approx. 11%. The Biotechnology Division 
contributed EUR35.2 million (PY: EUR34.7 mn) and the Mechatronics 
Division EUR13.5 million (PY: EUR13.6 mn) to these earnings. Actual 
EBITA of the Sartorius Group was EUR35.8 million (PY: EUR35.0 mn).
We have adjusted our sales revenue and earnings forecast for 2007 
somewhat downward, particularly due to the unfavorable development of
the exchange rates during the past months. For 2007, pro forma sales 
revenue for the entire Group is expected to rise to over EUR630 
million (previous forecast: EUR650-670 mn) to which the Biotechnology
Division will contribute more than EUR375 million and the 
Mechatronics Division more than EUR255 million.
Based on this expected growth and considering the negative impact of 
about 0.5 of a percentage point on the EBITA margin due to the 
devaluation of the U.S. dollar, we assume that we will reach a pro 
forma underlying EBITA margin of around 11.0% to 11.5% (previously 
about 12%). For the Biotechnology Division, we anticipate achieving a
pro forma underlying EBITA margin of 13.0% to 13.5% (previously about
14%); for the Mechatronics Division, this figure is expected to reach
8.5% to 9.0% (previously about 9%). This forecast does not include 
effects entailed by selling Sartorius Bearing Technology GmbH.
For fiscal 2008, the company expects to post gains in sales revenue 
and profitability for both divisions. The Biotechnology division 
anticipates sales revenue to grow more than 12,0% in constant 
currencies. Sales revenue in constant currencies for the Mechatronics
division is estimated to grow more than 5%. In both divisions, EBITA 
is targeted to increase overproportionately, so this margin for the 
entire Group is anticipated to rise to approximately 12,0%.
end of announcement                               euro adhoc 31.10.2007 15:37:52

Further inquiry note:

Andreas Wiederhold
Treasury & Investor Relations
Telefon: +49 (0)551 308-1668
E-Mail: andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / official dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade

Weitere Storys: Sartorius AG
Weitere Storys: Sartorius AG